ChemoCentryx is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing orally administered therapeutics for autoimmune diseases, inflammatory disorders, and cancer in the United States. Its clinical drug candidates include CCX140, which has completed Phase II clinical trials for the treatment of diabetic nephropathy; CCX872, an orally administered inhibitor in Phase Ib clinical trials for pancreatic cancer; and CCX168, which has completed Phase II clinical trials for anti-neutrophil cytoplasmic anti-body associated renal vasculitis.
ChemoCentryx Inc's ticker is CCXI
The company's shares trade on the NASDAQ stock exchange
They are based in San Carlos, California
There are 51-200 employees working at ChemoCentryx Inc
It is http://www.chemocentryx.com/
ChemoCentryx Inc is in the Healthcare sector
ChemoCentryx Inc is in the Biotechnology industry
The following five companies are ChemoCentryx Inc's industry peers: